1. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma
- Author
-
Emily C. N. Lawrence, Michelle Guo, Turner D. Schwartz, Jie Wu, Jingwen Lu, Sergei Nikonov, Jacob K. Sterling, and Qi N. Cui
- Subjects
glaucoma ,neuroprotection ,glucagon-like peptide-1 receptor agonist ,retinal ganglion cell (RGC) ,optic nerve (ON) ,microglia ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Glaucomatous neurodegeneration, a blinding disease affecting millions worldwide, has a need for the exploration of new and effective therapies. Previously, the glucagon-like peptide-1 receptor (GLP-1R) agonist NLY01 was shown to reduce microglia/macrophage activation, rescuing retinal ganglion cells after IOP elevation in an animal model of glaucoma. GLP-1R agonist use is also associated with a reduced risk for glaucoma in patients with diabetes. In this study, we demonstrate that several commercially available GLP-1R agonists, administered either systemically or topically, hold protective potential in a mouse model of hypertensive glaucoma. Further, the resulting neuroprotection likely occurs through the same pathways previously shown for NLY01. This work contributes to a growing body of evidence suggesting that GLP-1R agonists represent a viable therapeutic option for glaucoma.
- Published
- 2023
- Full Text
- View/download PDF